Product Images Tadalafil
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 10 images provide visual information about the product associated with Tadalafil NDC 71205-418 by Proficient Rx Lp, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
tadalafil structural formula - image 1
71205-418-30 - image 12
This is a description of a medication called Tadalafil 10mg, which comes in a bottle of 30 oval-shaped, yellow, film-coated tablets. Each tablet contains 10mg of tadalafil, USP, and is embossed with "TEVA" on one side and "3018" on the other. The medication is manufactured in Israel by TEVA PHARMACEUTICAL IND. LTD and labeled by Proficent Rx LP. The lot number of the medication is 00000 and its expiration date is 00/00/00. The medication is stored at a temperature of 20°-25°C (68°-77°F) and should be kept out of the reach of children. The GTIN number is 0371205418304.*
Figure 1: Mean Maximal Change in Blood Pressure (Tadalafil Minus Placebo, Point Estimate With 90% CI) in Response to Sublingual Nitroglycerin at 2 (Supine Only), 4, 8, 24, 48, 72, and 96 Hours After the Last Dose of Tadalafil 20 mg or Placebo - image 2
Figure 2: Doxazosin Study 1: Mean Change from Baseline in Systolic Blood Pressure - image 3
This appears to be a chart or graph showing the effect of two different medications on the standing and supine systolic blood pressure, with time post-dose in hours on the x-axis and blood pressure in mmHg on the y-axis. One medication is "Tacalafi 20 mg & doxazosin 8 mg" and the other is a placebo with doxazosin 8 mg. We can see values plotted for different time intervals on the x-axis.*
Figure 3: Doxazosin Study 2 (Part C): Mean Change from Time-Matched Baseline in Systolic Blood Pressure - image 4
This text provides information about the administration of different medications at different times, including tadalafil and doxazosin. The data also includes measurements of systolic blood pressure in mmHg. However, it is not clear what study or experiment this information is based on.*
Figure 4: Plasma Tadalafil Concentrations (Mean ± SD) Following a Single 20 mg Tadalafil Dose and Single and Once Daily Multiple Doses of 5 mg - image 5
This is a graph that shows the concentration of plasma tadalafil in mcg/L over time in hours. There are three lines on the graph which represent: a single dose of 20 mg tadalafil, a single dose of 5 mg tadalafil, and once-daily 5 mg tadalafil after 5 consecutive days of administration.*
Figure 5: Mean IPSS Changes in BPH Patients by Visit in Study J - image 6
This appears to be a result table for a clinical trial evaluating Tadalafil at a 5mg dose. The table displays the total score of an assessment called "IPSS" over a period of 8 and 12 weeks of treatment, as well as a placebo comparison. However, there is not enough context to determine the specific condition being treated or the design of the study.*
Figure 6: Mean IPSS Changes in BPH Patients by Visit in Study K - image 7
Figure 7: Mean Total IPSS Changes By Visit in BPH Patients Taking Tadalafil for Once Daily Use Together with Finasteride - image 8
Figure 8: Mean IPSS Changes in ED/BPH Patients by Visit in Study L - image 9
The text describes the change from baseline in International Prostate Symptom Score (IPSS) total score for a treatment with Tadalafil 5mg compared to a placebo. The chart shows the significant improvement in IPSS total score with Tadalafil 5mg compared to placebo over a treatment duration of weeks.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.